Fmr Trimmed Its Celldex Therapeutics New (CLDX) Stake by $1.62 Million as Stock Declined; As Mettler Toledo Intl (MTD) Share Price Rose, Holder Baldwin Investment Management Has Cut Holding

February 15, 2018 - By Richard Conner

Fmr Llc decreased its stake in Celldex Therapeutics Inc New (CLDX) by 8.3% based on its latest 2017Q3 regulatory filing with the SEC. Fmr Llc sold 809,608 shares as the company’s stock declined 11.75% while stock markets rallied. The institutional investor held 8.94 million shares of the health care company at the end of 2017Q3, valued at $25.58M, down from 9.75 million at the end of the previous reported quarter. Fmr Llc who had been investing in Celldex Therapeutics Inc New for a number of months, seems to be less bullish one the $311.41 million market cap company. The stock decreased 1.29% or $0.03 during the last trading session, reaching $2.29. About 1.34M shares traded or 17.15% up from the average. Celldex Therapeutics, Inc. (NASDAQ:CLDX) has declined 20.62% since February 15, 2017 and is downtrending. It has underperformed by 37.32% the S&P500.

Baldwin Investment Management Llc decreased its stake in Mettler Toledo Intl Inc (MTD) by 13.8% based on its latest 2017Q3 regulatory filing with the SEC. Baldwin Investment Management Llc sold 724 shares as the company’s stock rose 19.62% with the market. The institutional investor held 4,523 shares of the capital goods company at the end of 2017Q3, valued at $2.83 million, down from 5,247 at the end of the previous reported quarter. Baldwin Investment Management Llc who had been investing in Mettler Toledo Intl Inc for a number of months, seems to be less bullish one the $15.91B market cap company. The stock increased 1.79% or $10.98 during the last trading session, reaching $624.67. About 177,571 shares traded or 11.19% up from the average. Mettler-Toledo International Inc. (NYSE:MTD) has risen 55.25% since February 15, 2017 and is uptrending. It has outperformed by 38.55% the S&P500.

Analysts await Celldex Therapeutics, Inc. (NASDAQ:CLDX) to report earnings on March, 13. They expect $-0.20 EPS, up 33.33% or $0.10 from last year’s $-0.3 per share. After $-0.14 actual EPS reported by Celldex Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 42.86% negative EPS growth.

Fmr Llc, which manages about $827.12 billion US Long portfolio, upped its stake in Canadian Nat Res Ltd (NYSE:CNQ) by 1.40 million shares to 26.60M shares, valued at $890.97 million in 2017Q3, according to the filing. It also increased its holding in Microsoft Corp (NASDAQ:MSFT) by 2.74M shares in the quarter, for a total of 175.92M shares, and has risen its stake in Forward Air Corp (NASDAQ:FWRD).

Among 13 analysts covering Celldex Therapeutics (NASDAQ:CLDX), 8 have Buy rating, 0 Sell and 5 Hold. Therefore 62% are positive. Celldex Therapeutics had 24 analyst reports since August 11, 2015 according to SRatingsIntel. On Monday, March 7 the stock rating was downgraded by Wedbush to “Neutral”. The rating was maintained by WBB Securities on Wednesday, December 6 with “Buy”. Oppenheimer downgraded the stock to “Perform” rating in Monday, March 7 report. H.C. Wainwright maintained it with “Buy” rating and $1000 target in Wednesday, August 9 report. The rating was downgraded by Leerink Swann on Monday, March 7 to “Market Perform”. As per Tuesday, June 6, the company rating was maintained by Cowen & Co. The stock of Celldex Therapeutics, Inc. (NASDAQ:CLDX) earned “Buy” rating by TH Capital on Tuesday, August 11. Jefferies downgraded the stock to “Hold” rating in Tuesday, March 8 report. The firm earned “Buy” rating on Tuesday, August 11 by Brean Capital. Guggenheim downgraded the shares of CLDX in report on Monday, March 7 to “Neutral” rating.

Baldwin Investment Management Llc, which manages about $307.24M and $265.02 million US Long portfolio, upped its stake in Tal Education Group (NYSE:XRS) by 25,555 shares to 30,660 shares, valued at $1.03M in 2017Q3, according to the filing.

Among 11 analysts covering Mettler-toledo International Inc. (NYSE:MTD), 4 have Buy rating, 0 Sell and 7 Hold. Therefore 36% are positive. Mettler-toledo International Inc. had 27 analyst reports since August 3, 2015 according to SRatingsIntel. The rating was maintained by Jefferies with “Hold” on Friday, October 20. The stock has “Hold” rating by Jefferies on Thursday, August 31. The stock of Mettler-Toledo International Inc. (NYSE:MTD) earned “Outperform” rating by Wells Fargo on Thursday, July 13. Bank of America maintained Mettler-Toledo International Inc. (NYSE:MTD) rating on Monday, October 9. Bank of America has “Buy” rating and $710 target. As per Thursday, June 23, the company rating was downgraded by Citigroup. Jefferies maintained it with “Hold” rating and $550 target in Tuesday, June 20 report. Robert W. Baird maintained Mettler-Toledo International Inc. (NYSE:MTD) on Friday, November 3 with “Neutral” rating. The rating was upgraded by Bank of America to “Buy” on Wednesday, August 31. The company was maintained on Monday, February 12 by Robert W. Baird. The stock of Mettler-Toledo International Inc. (NYSE:MTD) earned “Buy” rating by Goldman Sachs on Tuesday, September 26.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts